Compounded GLP-1 ban: What providers need to know
In a recent regulatory shift, the FDA has ended the allowance for compounding pharmacies to produce copycat versions of popular GLP-1 receptor agonists. Here’s what you need to know.
PRESCRIBING SEMAGLUTIDE: The Importance of Shared Decision-Making
GLP-1 receptor agonists (GLP-1 RAs), of which semaglutide is an example, have emerged as a prominent therapeutic option for managing type 2 diabetes.